Erratum: Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial (American Journal of Nephrology (2015) 42 (265-273) DOI: 10.1159/000441364);Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial

American Journal of Nephrology

Volumn 42, Issue 4, 2015, Pages 265-273

  Lundwall, Kristina ^a   Jörneskog, Gun ^a   Jacobson, Stefan H ^a   Spaak, Jonas ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Cardiovascular risk; Chronic kidney disease; Endothelial function; Vascular function; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ACETYLCHOLINE; C REACTIVE PROTEIN; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; BONE DENSITY CONSERVATION AGENT; CALCITRIOL RECEPTOR; ERGOCALCIFEROL;

AGED; ALBUMINURIA; ARTICLE; BLOOD VESSEL PARAMETERS; CAPILLARY BLOOD VELOCITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ECHOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FLOW MEDIATED VASODILATATION; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; IONTOPHORESIS; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; MALE; MICROCIRCULATION; MUSCLE SYMPATHETIC NERVE ACTIVITY; NEUROGRAPHY; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TONOMETRY; TREATMENT DURATION; VASCULAR DISEASE; ADRENERGIC SYSTEM; AGONISTS; ANGIOSCOPY; ARTERIAL STIFFNESS; BRACHIAL ARTERY; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; BONE DENSITY CONSERVATION AGENTS; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ERGOCALCIFEROLS; FEMALE; HUMANS; MALE; MICROCIRCULATION; MICROSCOPIC ANGIOSCOPY; MICROVESSELS; MIDDLE AGED; PULSE WAVE ANALYSIS; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VASCULAR STIFFNESS; VASODILATION;

EID: 84945156647     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000490717     Document Type: Erratum

References (40)

1. Leonard O, Spaak J, Goldsmith D: Regression of vascular calcification in chronic kidney disease-feasible or fantasy? A review of the clinical evidence. Br J Clin Pharmacol 2013; 76: 560-572.
2. Anavekar NS, Pfeffer MA: Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 2004; 92:S11-S15.
3. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
4. Flammer AJ, Anderson T, Celermajer DS, et al: The assessment of endothelial function: from research into clinical practice. Circulation 2012; 126: 753-767.
5. Chitalia N, Ismail T, Tooth L, et al: Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One 2014; 9:e91363.
6. Stam F, van Guldener C, Becker A, et al: Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-545.
7. Yeboah J, Folsom AR, Burke GL, et al: Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009; 120: 502-509.
8. Bolton CH, Downs LG, Victory JG, et al: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001; 16: 1189-1197.
9. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD: Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003; 18: 892-898.
10. Vink EE, de Jager RL, Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013; 15: 95-101.
11. Wang TJ, Pencina MJ, Booth SL, et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
12. Martins D, Wolf M, Pan D, Zadshir A, Tareen N: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167: 1159-1165.
13. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A: Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther 2013; 20: 480-486.
14. Teng M, Wolf M, Ofsthun MN, et al: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
15. Alborzi P, Patel NA, Peterson C, et al: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
16. de Zeeuw D, Agarwal R, Amdahl M, et al: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
17. Thadhani R, Wenger J, Tamez H, et al: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.
18. Friedman TC, Norris KC: The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab 2002; 13: 189-194.
19. Levin A, Li Y: Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005; 68: 1973-1981.
20. Forman JP, Williams JS, Fisher ND: Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010; 55: 1283-1288.
21. Gunta SS, Thadhani RI, Mak RH: The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol 2013; 9: 337-347.
22. Mathieu C, Adorini L: The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8: 174-179.
23. Griffin MD, Lutz W, Phan VA, Bachman LA, Mckean DJ, Kumar R: Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptordependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 6800-6805.
24. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, et al: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-796.
25. Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM: Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin D deficiency: an exploratory, double blind, randomised controlled trial. PLoS One 2014; 9: e99461.
26. Zoccali C, Curatola G, Panuccio V, et al: Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 2014; 64: 1005-1011.
27. Laurent S, Cockcroft J, Van Bortel L, et al: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
28. Wilkinson IB, Fuchs SA, Jansen IM, et al: Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998; 16: 2079-2084.
29. Ostlund E, Al-Nashi M, Hamad RR, et al: Normalized endothelial function but sustained cardiovascular risk profile 11 years following a pregnancy complicated by preeclampsia. Hypertens Res 2013; 36: 1081-1087.
30. Corretti MC, Anderson TJ, Benjamin EJ, et al: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
31. Tehrani S, Mobarrez F, Lins PE, Adamson U, Wallen HN, Jorneskog G: Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes. Diab Vasc Dis Res 2013; 10: 483-488.
32. Jorneskog G, Brismar K, Fagrell B: Pronounced skin capillary ischemia in the feet of diabetic patients with bad metabolic control. Diabetologia 1998; 41: 410-415.
33. Bollinger A, Fagrell B: Clinical Capillaroscopy: A Guide to Its Use in Clinical Research and Practice. Lewistone, Hogrefe & Huber Publishers, 1990.
34. Ando S, Dajani HR, Floras JS: Frequency domain characteristics of muscle sympathetic nerve activity in heart failure and healthy humans. Am J Physiol 1997; 273:R205-R212.
35. Spaak J, Egri ZJ, Kubo T, et al: Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea. Hypertension 2005; 46: 1327-1332.
36. Marckmann P, Agerskov H, Thineshkumar S, et al: Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523-3531.
37. Hemmelgarn BR, Zhang J, Manns BJ, et al: Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006; 69: 2155-2161.
38. Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K: Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2012; 16: 622-628.
39. Jorneskog G, Kalani M, Kuhl J, et al: Early microvascular dysfunction in healthy normalweight males with heredity for type 2 diabetes. Diabetes Care 2005; 28: 1495-1497.
40. Garg R, Rao AD, Baimas-george M, Hurwitz S, Foster C, Shah RV, et al: Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015; 64: 236-242.